Next generation sequencing in adult patients with glioblastoma in Switzerland: a multi-centre decision analysis.

Publication

Next generation sequencing in adult patients with glioblastoma in Switzerland: a multi-centre decision analysis.

Journal Paper/Review - Apr 29, 2022

Zeitlberger A M, Putora Paul Martin, Hofer S, Schucht P, Migliorini D, Hottinger A F, Roelcke U, Läubli H, Spina P, Bozinov Oliver, Weller M, Neidert M, Hundsberger Thomas

Citation

Zeitlberger A, Putora P, Hofer S, Schucht P, Migliorini D, Hottinger A, Roelcke U, Läubli H, Spina P, Bozinov O, Weller M, Neidert M, Hundsberger T. Next generation sequencing in adult patients with glioblastoma in Switzerland: a multi-centre decision analysis. J Neurooncol 2022; 158:359-367.

Type

Journal Paper/Review (English)

Journal

J Neurooncol 2022; 158

Publication Date

Apr 29, 2022

Issn Electronic

1573-7373

Pages

359-367

Brief description/objective

Glioblastoma is the most common malignant primary brain tumour in adults and driven by various genomic alterations. Next generation sequencing (NGS) provides timely information about the genetic landscape of tumours and might detect targetable mutations. To date, differences exist in the application and NGS assays used as it remains unclear to what extent these variants may affect clinical decision making. In this survey-based study, we investigated the use of NGS in adult patients with glioblastoma in Switzerland.